Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female, African American (self-reported), ≥12 years of age~* Moderate to severe asthma requiring treatment with an inhaled corticosteroid~* Diagnosis of asthma for at least 6 months~Exclusion Criteria:~* Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)~* Any significant disease or disorder that may jeopardize a subject's safety

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Symbicort (Type: EXPERIMENTAL): Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
- Budesonide (Type: EXPERIMENTAL): Budesonide HFA pMDI 160 ug x 2 actuations BID

Based on this trial design, predict the completion outcome and termination type (if applicable).